Björn Pilebro

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

^99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis

Björn Pilebro, Ole B. Suhr, Ulf Näslund et al. · Upsala Journal of Medical Sciences · 2016 · 121 citations · Full text

Medicine, Molecular Genetics, Pathobiology +14

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy

Marianna Fontana, Scott D. Solomon, Jessica Kachadourian et al. · New England Journal of Medicine · 2024 · 113 citations · Full text

Medicine, Cardiology, Pharmacology +17

Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)

Björn Pilebro, Sandra Arvidsson, Per Lindqvist et al. · Journal of Nuclear Cardiology · 2016 · 110 citations · Full text

Medicine, Cardiology, Nuclear Medicine +16

Prevalence of Wild Type Transtyrethin Cardiac Amyloidosis in a Heart Failure Clinic

Krister Lindmark, Björn Pilebro, Torbjörn Sundström et al. · ESC Heart Failure · 2020 · 81 citations · Full text

Medicine, Cardiology, Internal Medicine +15